See Credit Details Below
Why You Should Attend
Drug pricing has been a key policy issue in all branches of the federal government for some time, and the topic continues to attract considerable public attention. Despite the change in administrations, the political desire to address drug pricing – whether through government-led negotiation of drug prices, international reference pricing, inflation-based penalties, or otherwise – is stronger than ever. Indeed, the topic of drug pricing reform has drawn bipartisan support and attention at the federal and state levels. At the same time, the COVID-19 pandemic has demonstrated the importance and urgency of biopharmaceutical innovation. Scientific knowledge has evolved such that the drugs and biologics launched during upcoming years are expected to be groundbreaking and transformative when it comes to patient lives and wellbeing.
Against this backdrop, the stakes for companies that have businesses related to the pharmaceutical supply chain have never been higher. Beyond this, even companies that do not conduct business in the health care arena have a stake in pharmaceutical pricing and reimbursement as they sponsor health plans for employees and their family members and confront new regulatory requirements that mandate transparency around drug costs in connection with these plans.
It is increasingly important for a wide variety of legal practitioners and allied professionals to understand how drugs are priced and reimbursed, as well as the key (and evolving) legal requirements and business innovations that govern pricing and reimbursement.
What You Will Learn
This program will cover key legal and policy issues related to drug pricing and reimbursement. It reviews the basics: how drugs are priced and reimbursed, the role of different entities within the pharmaceutical supply chain, and the key federal and state legal requirements that govern pricing and reimbursement. The program also analyzes the role of employers (as sponsors of health plans) in managing costs in connection with benefit plans, and emerging transparency requirements that pertain to employer-sponsored insurance (and certain other forms of health insurance coverage).
The program also will examine select emerging trends and prospective legal reforms that relate to drug pricing and reimbursement – including trends relating to the shift to value-based payment for drugs – and strategic issues that companies may confront related to drug pricing and reimbursement.
Who Should Attend
This program is designed for law firm attorneys and corporate counsel, including (i) counsel with a business model that intersects with pharmaceuticals and (ii) counsel that need to better understand drug pricing and reimbursement as it impacts employer sponsors of health benefit plans. The program also generally applies to practitioners and allied professionals who wish to deepen their understanding of issues related to drug pricing and reimbursement, especially in light of the rapidly evolving legal and business changes in this arena.